HEALEY ALS Platform Trial Webinar: March 19, 2026 | Regimen I (NUZ-001) Science

Why It Matters

Regimen I accelerates ALS drug development while lowering costs, and NUZ001 could become the first disease‑modifying therapy targeting TDP‑43 pathology, reshaping treatment prospects for patients.

Key Takeaways

• Healy ALS platform trial expands to Regimen I with NUZ001.
• Trial redesign reduces placebo ratio, extends randomization to nine months.
• NUZ001 targets mTOR to boost autophagy and clear TDP‑43 aggregates.
• Phase 1/2 data show safety, 31% slower ALSFRS‑R decline versus controls.
• Network now includes 81 sites, 1,300 participants, 300k biosamples.

Summary

The webinar introduced Regimen I of the Healy ALS platform trial, the next phase of a community‑driven effort to evaluate new therapies. Led by Dr. James Barry and partners from New Horizon, the session focused on the investigational mTOR inhibitor NUZ001, which aims to enhance autophagy and clear pathogenic TDP‑43 aggregates.

The trial has been reengineered to cut placebo exposure, using a 3:1 randomization and extending the blinded period to nine months to improve statistical power. Remote visits and refined inclusion criteria (≤2 years from symptom onset) further streamline enrollment across 81 U.S. sites, now supporting over 1,300 participants and a repository of 300,000 biospecimens.

NUZ001’s preclinical work demonstrated reduced TDP‑43 clumping, and early human studies reported a favorable safety profile with only modest adverse events. In an open‑label extension, treated patients showed a 31 % slower decline in ALSFRS‑R scores compared with matched controls from the PROACT database, suggesting potential disease‑modifying activity.

If successful, Regimen I could halve the time and cut a third of the cost of bringing ALS drugs to market, offering a faster path to effective therapies and providing a template for adaptive platform trials in other neurodegenerative diseases.

Original Description

Co-lead investigators James Berry, MD, MPH of Massachusetts General Hospital and Michael Weiss, MD of the University of Washington were joined by scientists from Neurizon Therapeutics to discuss the science behind NUZ-001 (the investigational product being tested in Regimen I of the HEALEY ALS Platform Trial) and answer questions from the audience.

Visit the Mass General website to register for future Platform Trial webinars: https://www.massgeneral.org/neurology/als/research/platform-trial-news

Sign up for the ALS Link to stay up to date about news and research from the Sean M. Healey & AMG Center for ALS: https://lp.constantcontactpages.com/sl/wQfOqgA/ALSLink

Follow MGH Neurology on Facebook (https://www.facebook.com/MGHNeurology/) and X (https://x.com/MGHNeurology)